CYAD — Celyad Oncology SA Share News
0.000.00%
Last trade - 00:00- €9.93m
- €9.80m
- €0.02m
Brief: Celyad Oncology To Discontinue Development Of CYAD-101
Brief: Cellistic To Acquire Celyad Oncology's Manufacturing Business Unit For EUR 6 Mln
Brief: Celyad Oncology H1 Net Loss Narrows To EUR 14.4 Mln
U.S. STOCKS ON THE MOVE-Boeing Co, Celyad, EVO Payments
Celyad surges as FDA lifts clinical hold on cancer therapy study
Brief: Celyad Oncology Says FDA Lifts Clinical Hold Of CYAD-101-002 Phase 1b Trial
Brief: Celyad Oncology: Hilde Windels Named As Chairwoman Of Board Of Directors, Effective Immediately
Brief: Euronext Announces Quarterly Review Of BEL Family Indices
Brief: Celyad Oncology Q1 Cash At EUR 20.5 Million
Brief: Celyad Oncology FY Operating Loss Widens To EUR 26.4 Million
Brief: Celyad Oncology Announces Clinical Hold Of CYAD-101-002 Phase 1b Trial
Brief: Celyad Oncology Announces Voluntary Pause Of CYAD-101-002 Phase 1b Trial
Brief: Celyad Oncology Provides Outlook For 2022
Brief: Celyad Oncology End-Dec Unaudited Treasury Position Of EUR 30 Mln
Brief: Celyad Oncology Announces First Patient Dosed In Keynote-B79 Phase 1B Trial
Brief: CFIP CLYD, Affiliate Of Fortress Investment Group, Holds 28.77% In Celyad Oncology
Brief: Celyad Oncology To Present Updates On shRNA-Based CAR T Programs
Brief: Celyad Oncology Announces Closing Of $32.5 Mln Private Placement With Fortress Investment Group Affiliate
Celyad's capital raise increases visibility, stock heads for best day in 3 years